Cargando…
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature
RATIONAL: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are emerging problems in several countries. These infections require long and expensive treatment regimens. Recently, 2 new drugs, bedaquiline and delamanid, have been approved in several countries for use in...
Autores principales: | Esposito, Susanna, Bosis, Samantha, Tadolini, Marina, Bianchini, Sonia, Migliori, Giovanni Battista, Principi, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120920/ https://www.ncbi.nlm.nih.gov/pubmed/27861363 http://dx.doi.org/10.1097/MD.0000000000005347 |
Ejemplares similares
-
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017) -
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016) -
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021) -
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017) -
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)